Medical Marijuana Inc (OTCMKTS:MJNA) reported that its major investment firm Axim Biotechnologies Inc(OTCMKTS:AXIM) has submitted an IP application with the WIPO on a proprietary process to extract THC-A from cannabis plants and to get THC with higher purity than old processes being applied in the market today.
THC is the most usually known Cannabinoid resulting from the Cannabis plant. The filed IP would offer protection to the extraction method invention of THC-A, from the cannabis plant utilizing a solvent where the yield is around 50 – 70% pertaining to THC-A content in the preliminary material. An inorganic base solution or neutral metal salt adjusted to basic pH and saturated with the metal neutral salt allows separation of the THC-A sheet and considerably enhances the yield. Later THC-A is decarboxylated in an ethanol/ water solution to purify THC at over 95%.
The IP was produced in partnership with Syncom B.V., a Netherlands-based leading firm in custom synthesis solutions for the biotech and pharmaceutical industry. Dr. Stuart Titus, the CEO of Medical Marijuana, said that they are extremely thrilled to witness that AXIM has submitted this IP as it shows the first phase of a chain of processes in advancement of revolutionary and novel drug products all dependent on AXIM’s propriety IP.
It is another instance of how AXIM is at the front of the cannabis biotechnology market. This extraction process will change how THC can be used in products in the open and future new opportunities for the industry as a whole.
Medical Marijuana CEO continued that the THC purity level that AXIM can achieve via this invention will untimely showcase a record achievement in the regulating of cannabis based products. With around 440 marijuana strains in presence with varying levels of CBDs, trying to make this into a regulated medicine has shown a real challenge for the research group. Now AXIM has solved these problems and they consider this will permit for future cannabis based drug advancement opportunities.